Pozen dials down its R&D efforts; Kindred tanks as dog drug comes up short;

@FierceBiotech: Low levels of enzyme in Alzheimer's brains suggest new drug target. More from FierceBiotech Research | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test. Report | Follow @JohnCFierce

@DamianFierce: A glimpse at the glamorous hedonism that runs rampant in Big Pharma. Image | Follow @DamianFierce

@EmilyMFierce: Parents more likely to vaccinate kids against measles when child's, not society's, benefits are stressed. FierceVaccines story | Follow @EmilyMFierce

> Pozen ($POZN) is slowly backing away from drug development, walking back R&D partnerships and turning its attention to in-licensing and royalty deals. Story

> Animal biotech Kindred Biosciences ($KIN) watched its shares plummet after revealing that its lead candidate failed to beat placebo in a study on dogs with osteoarthritis. News

> OncoGenex ($OGXI) and partner Teva ($TEVA) are staying the course on a Phase III trial of the cancer treatment custirsen, clearing the first futility analysis in a study on non-small cell lung cancer. More

Medical Device News

@FierceMedDev: Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. ICYMI yesterday | Follow @FierceMedDev

@VarunSaxena2: UPDATED with table of deadlines: FDA clarifies UDI requirements with new guidance. Story | Follow @VarunSaxena2

@EmilyWFierce: Pruning of synapses in brain could provide clues to how autism develops in children, say scientists. More from the NYT | Follow @EmilyWFierce

> Google Ventures, Kleiner Perkins back enterprise wearables startup. More

> FDA clears AliveCor smartphone plug-in heart monitor to detect atrial fibrillation. Article

> Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. Story

Pharma News

@FiercePharma: Top-read news in FP Thurs: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. Article | Follow @FiercePharma

@TracyStaton: ICYMI this week:  CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: DEA tightens prescribing, limits refills on opioid combo pills like #Vicodin. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier - Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020. Article | Follow @CarlyHFierce

> 2014 has potential to exceed milestone year of 2009 for M&A action. News

> Pfizer, BMS pad bright Q2 with new FDA nod for Eliquis. More

> DEA tightens opioid dispensing rules amid controversy over abuse. Story